Orthofix reported second-quarter 2026 results on 5 August and raised its full-year guidance. The headline numbers are modest — net sales of $210.9 million, up 3.8% reported — but two lines in the report carry real weight for the fracture care market: Global Limb Reconstruction grew 13.2%, and Medicare restored reimbursement for non-invasive bone growth stimulators to its prior level. One signals demand for complex fracture and limb salvage hardware; the other reopens a reimbursement channel for fracture healing technology.
The quarter in numbers
- Net sales of $210.9 million, up 3.8% reported and 4.7% pro forma constant currency.
- Global Limb Reconstruction sales of $37.7 million, up 13.2% reported and 11.0% in constant currency.
- Global Spine sales of $173.2 million, up 3.5%; Therapeutic Solutions up 2.5% to $64.2 million.
- Reported net loss of $15.8 million; adjusted EBITDA of $20.1 million, a 9.6% margin.
- Full-year net sales guidance raised to $845–855 million and adjusted EBITDA to $95–98 million.
Management credited double-digit growth in limb reconstruction and spine fixation, plus the reimbursement restoration, for the confidence to raise guidance. Cash fell from $120.9 million to $104.4 million in the quarter, a decline the company attributes to arbitration and settlement payments tied to claims from three former executives terminated in 2023.
Limb reconstruction keeps compounding
The 13% growth in limb reconstruction continues a run built on the TRUELOK Elevate external fixation system and the FITBONE bone transport system. This segment matters beyond its size: limb reconstruction sits at the complex end of fracture care — bone transport after traumatic bone loss, deformity correction after malunion, salvage of limbs that would otherwise face amputation. Double-digit growth here says hospitals are treating more complex fracture sequelae surgically rather than defaulting to amputation or prolonged conservative care, and it pulls demand through the whole fixation chain, from ring fixators to the tibia and fibula plating used in reconstruction adjuncts.
The bone growth stimulator decision
The more quietly significant item is reimbursement. Medicare payment for non-invasive bone growth stimulators was restored to its prior level during the quarter, ending a temporary headwind that had pressed the Therapeutic Solutions segment. Bone growth stimulators occupy a specific niche in fracture care: they are prescribed for fractures at risk of nonunion and for established nonunions where the surgeon wants a biological push without immediate reoperation. Orthofix noted its AccelStim device is continuing to drive fracture market growth. With the payment channel restored, prescribing volume in this niche should normalize in the second half — and every nonunion pathway still ends with fixation hardware when stimulation fails, from revision screws to fresh plating.
What this signals for fracture care buyers
Three practical readings for hospitals and distributors. First, complex fracture and limb salvage procedures are growing faster than routine orthopedics, so formulary depth in reconstruction-adjacent fixation matters more each year. Second, restored stimulator reimbursement means nonunion protocols will run their full course again — buyers should expect stimulator referrals before revision plating, not instead of it. Third, mid-cap orthopedic companies raising guidance while the giants trim theirs is a reminder that fracture care demand is spread across many suppliers, and single-source dependency is a procurement risk worth managing.
The BoneCraft angle
BoneCraft is an independent distributor of genuine orthopedic trauma implants. Nonunion repair, limb reconstruction adjuncts and revision fixation all run on the same hardware families we stock — plates, nails and screws held in warehouse inventory with factory lot documentation. Contact our team for current availability.
Sources
- Orthofix Reports Second Quarter 2026 Results — official release, 5 August 2026
- Orthofix Q2 2026 Investor Presentation — segment highlights and guidance detail
- Morningstar / Business Wire — Orthofix Q2 2026 release with guidance raise
Orthofix, TRUELOK, FITBONE, AccelStim and VIRATA are trademarks of their respective owner. BoneCraft is an independent distributor of genuine orthopedic trauma implants and is not affiliated with, sponsored by, or endorsed by Orthofix or any other company mentioned.
-
BrandName Team
Process Media Manufacturer Since 2010
pproduces tower packing, molecular sieves, ceramic grinding media and other process media from our Pingxiang production base. We supply to industrial projects in over 100 countries.
